Monday, 25 Mar 2019

You are here

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings.  Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

  1. Metanalysis of checkpoint inhibitor (nivolumab, pembrolizumab or atezolizumab) shows high rates of hypothyroidism (OR 7.6), pneumonitis (5.4), colitis (2.9), hypophysitis (3.4), rash (2.4), fatigue (32%), diarrhea (19%) and  a >20% frequency of arthraligia or back pain. https://t.co/1WMuRRCWZN
  2. Science Translocation of a gut microbe, Enterococcus gallinarum to tissues triggers autoimmunity in mice with a genetic predispositon to lupus. Vancomycin prevented mortality by suppressing E. gallinarum and eliminating pathogenic autoantibodies and T cells. https://t.co/02vZstzQ86
  3. An Italian 89 pt GPA study finds ENT involvement in 72%; they tend to be younger with less renal disease. Sinonasal symptoms were seen in 58% and otitis media/otomastoiditis in 35%. ENT involvement predicted better outcomes and milder GPA with risk of lower renal disease and mortality rate. https://t.co/UWjzzloxm9
  4. Comparing patients who travel by air vs. those by land to/from hospital after TKR, THR, finds 3 fold higher rates of venous thromboembolic events (VTE) (1.64% vs 0.58%) https://t.co/n5cu9eeqz6
  5. Opportunistic Infections in RA Rare with Biologics   
  6. Bone Marrow Edema Found in SI Joint of Athletes  
  7. Plaquenil During Lupus Pregnancy Lessens Flares 
  8. CARES Study- More CV Deaths with Febuxostat 

“A goal without a plan is just a wish.” ― Antoine de Saint-Exupéry (goals specific, measureable, attainable, realistic & timely - Christine Bundy)

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Many gout patients placed on febuxostat due to renal diseases. Could presence kidney problems raise risk adverse cardiovascular events for those on febuxostat?

More Like This

RheumNow Podcast – You Owe Me a DEXA (3.15.19)

Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.

RheumNow Podcast – Delays in Diagnosis (3.8.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Medical Meetings: Should I Stay or Should I Go?

Say a conference in your field was just announced. You think you "should" go, and you know you'll be choosing from many presentation opportunities that feature the latest research — which you want to know about. And you'll get to hang with like minds and talk about things that matter.

RheumNow Podcast – Scleroderma and the Lung (3.1.19)

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com

RheumNow Podcast - Death and Surgery (2-22-19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com: